Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.67 |
| ▸ | NOD1 | Q9Y239 | 4/20 | 0.46 |
| ▸ | CCKAR | P32238 | 3/20 | 0.43 |
| ▸ | CCKBR | P32239 | 3/20 | 0.43 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.41 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18697474 | 1.00 | GLP1R (0.67) | GLP1RNOD1CCKARCCKBRFOLH1 | |
| SCHEMBL13293965 | 1.00 | GLP1R (0.67) | GLP1RNOD1CCKARCCKBRFOLH1 | |
| SCHEMBL16182631 | 1.00 | GLP1R (0.67) | GLP1RNOD1CCKARCCKBRFOLH1 | |
| SCHEMBL12806533 | 1.00 | GLP1R (0.67) | GLP1RNOD1CCKARCCKBRFOLH1 | |
| SCHEMBL24284196 | 1.00 | GLP1R (0.67) | GLP1RNOD1CCKARCCKBRFOLH1 | |
| SCHEMBL12287742 | 1.00 | GLP1R (0.67) | GLP1RNOD1CCKARCCKBRFOLH1 | |
| SCHEMBL24198476 | 1.00 | GLP1R (0.67) | GLP1RNOD1CCKARCCKBRFOLH1 | |
| SCHEMBL23051891 | 1.00 | GLP1R (0.67) | GLP1RNOD1CCKARCCKBRFOLH1 | |
| SCHEMBL24899310 | 1.00 | GLP1R (0.67) | GLP1RNOD1CCKARCCKBRFOLH1 | |
| SCHEMBL20911267 | 1.00 | GLP1R (0.67) | GLP1RNOD1CCKARCCKBRFOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023227505-A1 | LIQUID PHARMACEUTICAL FORMULATIONS OF CNP COMPOUNDS | ASCENDIS PHARMA GROWTH DISORDERS A/S (DK) | 2023-11-30 | — | — | WO | disclosed |
| US-20230310616-A1 | LIQUID PHARMACEUTICAL COMPOSITIONS OF POLYPEPTIDE CONJUGATES AND METHODS OF USES THEREOF | BEIJING QL BIOPHARMACEUTICAL CO., LTD. (CN) | 2023-10-05 | — | — | US | disclosed |
| US-20230192799-A1 | CNP Variants and Conjugates Thereof | BIOMARIN PHARMACEUTICAL INC. | 2023-06-22 | — | — | US | disclosed |
| WO-2023110758-A1 | EFFECTIVE DOSES OF CNP CONJUGATES | ASCENDIS PHARMA GROWTH DISORDERS A/S (DK) | 2023-06-22 | — | — | WO | disclosed |
| US-11529394-B2 | Polypeptide conjugates and methods of uses | BEIJING QL BIOPHARMACEUTICAL CO., LTD. (CN) | 2022-12-20 | — | — | US | disclosed |
| US-20220133856-A1 | POLYPEPTIDE CONJUGATES AND METHODS OF USES | BEIJING QL BIOPHARMACEUTICAL CO., LTD. (CN) | 2022-05-05 | — | — | US | disclosed |
| US-20220016254-A1 | CONJUGATES OF FUSION PROTEINS OF GLP-1 AND FGF21 | BEIJING QL BIOPHARMACEUTICAL CO., LTD. (CN) | 2022-01-20 | — | — | US | disclosed |
| WO-2021055497-A1 | CNP VARIANTS AND CONJUGATES THEREOF | BIOMARIN PHARMACEUTICAL INC. (US) | 2021-03-25 | — | — | WO | disclosed |
| WO-2021037942-A1 | COMPSTATIN ANALOGUES AND THEIR MEDICAL USES | ZP SPV 3 K/S (DK) | 2021-03-04 | — | — | WO | disclosed |
| EP-3733694-A1 | GLUCAGON-RECEPTOR SELECTIVE POLYPEPTIDES AND METHODS OF USE THEREOF | Intarcia Therapeutics, Inc (US) | 2020-11-04 | — | — | EP | disclosed |
| WO-2019016306-A1 | BIFUNCTIONAL COMPOUNDS | NOVO NORDISK A/S (DK) | 2019-01-24 | — | — | WO | disclosed |
| WO-2017200943-A1 | GLUCAGON-RECEPTOR SELECTIVE POLYPEPTIDES AND METHODS OF USE THEREOF | INTARCIA THERAPEUTICS, INC. (US) | 2017-11-23 | — | — | WO | disclosed |
| US-20170258711-A1 | Fatty Acid Acylated D-Amino Acids for Oral Peptide Delivery | NOVO NORDISK AS (DK) | 2017-09-14 | — | — | US | disclosed |
| US-9732137-B2 | Semi-recombinant preparation of GLP-1 analogues | NOVO NORDISK A/S (DK) | 2017-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11529394-B2 | Polypeptide conjugates and methods of uses | GLP1R, GIPR, IAPP | GLP1R 1/4885NOD1 1241/4885CCKAR 24/4885 |
| US-20230310616-A1 | LIQUID PHARMACEUTICAL COMPOSITIONS OF POLYPEPTIDE CONJUGATES AND METHODS OF USES THEREOF | GLP1R, GIPR, IAPP | GLP1R 1/4885NOD1 621/4885CCKAR 15/4885 |
| US-20230192799-A1 | CNP Variants and Conjugates Thereof | NPPA, NPR1, NPR3 | GLP1R 68/4885NOD1 1222/4885CCKAR 1262/4885 |
| US-20220133856-A1 | POLYPEPTIDE CONJUGATES AND METHODS OF USES | GLP1R, GIPR, IAPP | GLP1R 1/4885NOD1 1241/4885CCKAR 24/4885 |
| US-20170258711-A1 | Fatty Acid Acylated D-Amino Acids for Oral Peptide Delivery | SLC27A1, SLC27A2, FABP2 | GLP1R 152/4885NOD1 4350/4885CCKAR 752/4885 |
| US-20220016254-A1 | CONJUGATES OF FUSION PROTEINS OF GLP-1 AND FGF21 | GLP1R, GIPR, FGFR1 | GLP1R 1/4885NOD1 1107/4885CCKAR 113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.